Get started
REPLIGEN CORPREPLIGEN CORPREPLIGEN CORP

REPLIGEN CORP

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Bonds

1RGEN chart


Full chart

1RGEN upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.08 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.40 EUR
Net income (FY)
‪−24.65 M‬ EUR
Revenue (FY)
‪612.85 M‬ EUR
Shares float
‪53.12 M‬
Beta (1Y)
0.77

Employees


Employees (FY)
‪1.78 K‬
Change (1Y)
−5 −0.28%
Revenue / Employee (1Y)
‪344.69 K‬ EUR
Net income / Employee (1Y)
‪−13.86 K‬ EUR

About Repligen Corporation


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Olivier Dominique Loeillot
Website
repligen.com
Headquarters
Waltham
Founded
1981
FIGI
BBG01TNWX468
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1RGEN news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

1RGEN highest yielding bonds


RGEN5964422
Repligen Corporation 1.0% 15-DEC-2028
Yield to maturity
1.32%
Maturity date
Dec 15, 2028

See all 1RGEN bonds 


Check out other big names from the same industry as 1RGEN.

Frequently Asked Questions


The current price of 1RGEN is 106.55 EUR — it hasn't changed in the past 24 hours. Watch REPLIGEN CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange REPLIGEN CORP stocks are traded under the ticker 1RGEN.
1RGEN stock has fallen by −4.91% compared to the previous week, the month change is a −15.50% fall, over the last year REPLIGEN CORP has showed a −15.50% decrease.
We've gathered analysts' opinions on REPLIGEN CORP future price: according to them, 1RGEN price has a max estimate of 195.69 EUR and a min estimate of 124.53 EUR. Watch 1RGEN chart and read a more detailed REPLIGEN CORP stock forecast: see what analysts think of REPLIGEN CORP and suggest that you do with its stocks.
1RGEN reached its all-time high on May 16, 2025 with the price of 129.70 EUR, and its all-time low was 106.55 EUR and was reached on May 23, 2025. View more price dynamics on 1RGEN chart.
See other stocks reaching their highest and lowest prices.
1RGEN stock is 0.00% volatile and has beta coefficient of 0.77. Track REPLIGEN CORP stock price on the chart and check out the list of the most volatile stocks — is REPLIGEN CORP there?
Today REPLIGEN CORP has the market capitalization of ‪6.03 B‬, it has increased by 1.92% over the last week.
Yes, you can track REPLIGEN CORP financials in yearly and quarterly reports right on TradingView.
REPLIGEN CORP is going to release the next earnings report on Aug 5, 2025. Keep track of upcoming events with our Earnings Calendar.
1RGEN earnings for the last quarter are 0.36 EUR per share, whereas the estimation was 0.32 EUR resulting in a 12.69% surprise. The estimated earnings for the next quarter are 0.35 EUR per share. See more details about REPLIGEN CORP earnings.
REPLIGEN CORP revenue for the last quarter amounts to ‪156.37 M‬ EUR, despite the estimated figure of ‪151.31 M‬ EUR. In the next quarter, revenue is expected to reach ‪154.85 M‬ EUR.
1RGEN net income for the last quarter is ‪5.39 M‬ EUR, while the quarter before that showed ‪−32.72 M‬ EUR of net income which accounts for 116.47% change. Track more REPLIGEN CORP financial stats to get the full picture.
No, 1RGEN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 29, 2025, the company has ‪1.78 K‬ employees. See our rating of the largest employees — is REPLIGEN CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REPLIGEN CORP EBITDA is ‪115.13 M‬ EUR, and current EBITDA margin is 17.21%. See more stats in REPLIGEN CORP financial statements.
Like other stocks, 1RGEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REPLIGEN CORP stock right from TradingView charts — choose your broker and connect to your account.